Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
ACT [NYSE]
Actavis plc
IndexS&P 500 P/E506.23 EPS (ttm)0.47 Insider Own0.40% Shs Outstand264.26M Perf Week2.89%
Market Cap62.88B Forward P/E14.54 EPS next Y16.37 Insider Trans33.80% Shs Float263.02M Perf Month9.11%
Income62.40M PEG25.54 EPS next Q3.09 Inst Own67.50% Short Float0.82% Perf Quarter9.65%
Sales10.11B P/S6.22 EPS this Y-793.40% Inst Trans9.44% Short Ratio0.93 Perf Half Y9.91%
Book/sh55.57 P/B4.28 EPS next Y23.35% ROA0.30% Target Price266.95 Perf Year72.80%
Cash/sh16.26 P/C14.64 EPS next 5Y19.83% ROE0.80% 52W Range135.50 - 239.58 Perf YTD41.62%
Dividend- P/FCF42.42 EPS past 5Y-35.20% ROI-3.00% 52W High-0.69% Beta0.36
Dividend %- Quick Ratio1.60 Sales past 5Y27.90% Gross Margin49.10% 52W Low75.59% ATR4.11
Employees19200 Current Ratio2.00 Sales Q/Q34.00% Oper. Margin15.20% RSI (14)73.71 Volatility2.11% 1.67%
OptionableYes Debt/Eq1.27 EPS Q/Q106.60% Profit Margin0.60% Rel Volume0.70 Prev Close237.09
ShortableYes LT Debt/Eq1.11 EarningsAug 05 BMO Payout0.00% Avg Volume2.31M Price237.93
Recom1.60 SMA203.35% SMA507.77% SMA20016.91% Volume1,616,406 Change0.35%
06-Aug-14Reiterated UBS Buy $237 → $254
02-Jul-14Reiterated CRT Capital Buy $245 → $275
27-Jun-14Initiated Canaccord Genuity Buy $275
12-May-14Upgrade RBC Capital Mkts Outperform → Top Pick $252 → $259
01-May-14Reiterated CRT Capital Buy $230 → $245
28-Apr-14Reiterated National Alliance Securities Buy $246 → $259
17-Apr-14Initiated National Alliance Securities Buy $246
21-Feb-14Reiterated RBC Capital Mkts Outperform $240 → $249
19-Feb-14Reiterated UBS Buy $202 → $237
19-Feb-14Reiterated CRT Capital Buy $210 → $230
19-Feb-14Reiterated Barclays Overweight $230 → $250
03-Feb-14Reiterated RBC Capital Mkts Outperform $202 → $222
03-Feb-14Reiterated Barclays Overweight $190 → $230
17-Jan-14Reiterated Argus Buy $180 → $198
07-Jan-14Initiated RBC Capital Mkts Outperform $202
30-Oct-13Reiterated Barclays Overweight $175 → $190
16-Sep-13Reiterated Barclays Overweight $140 → $175
30-Jul-13Reiterated Argus Buy $120 → $150
26-Jul-13Reiterated CRT Capital Buy $140 → $150
30-May-13Reiterated UBS Buy $120 → $155
18-Sep-14 10:00AM  Wall Street's Latest Tax Craze... And How To Profit StreetAuthority Network
10:00AM  Capitalize On Wall Street's Latest Tax Craze StreetAuthority Network
17-Sep-14 08:28AM  Why Salix Pharmaceuticals (SLXP) Stock Is Higher Today at TheStreet
03:15AM  [$$] New York Sues to Block Early Withdrawal of Alzheimer's Drug at The Wall Street Journal
01:30AM  [$$] New York Sues to Block Early Withdrawal of Alzheimer's Drug at The Wall Street Journal
01:20AM  [$$] New York Sues to Block Early Withdrawal of Alzheimer's Drug at The Wall Street Journal
12:35AM  [$$] New York Sues to Block Early Withdrawal of Alzheimer's Drug at The Wall Street Journal
16-Sep-14 11:21PM  [$$] New York Sues to Block Early Withdrawal of Alzheimer's Drug at The Wall Street Journal
10:53PM  [$$] New York Sues to Block Early Withdrawal of Alzheimer's Drug at The Wall Street Journal
09:25PM  [$$] New York Sues to Block Early Withdrawal of Alzheimer's Drug at The Wall Street Journal
05:51PM  [$$] New York Sues to Block Early Withdrawal of Alzheimer's Drug at The Wall Street Journal
05:21PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
02:12PM  Alzheimer's drug fight CNBC
11:50AM  [$$] New York Sues to Block Early Withdrawal of Alzheimer's Drug at The Wall Street Journal
11:19AM  [$$] New York Sues to Block Early Withdrawal of Alzheimer's Drug at The Wall Street Journal
09:23AM  [$$] New York Sues to Block Early Withdrawal of Alzheimer's Drug at The Wall Street Journal
15-Sep-14 09:27PM  NY attorney general sues Actavis and Forest Labs over Alzheimer's drug Reuters
08:36PM  Actavis Sued by New York Attorney General Over Namenda Switch at Bloomberg
02:37PM  IBD 50 Names Hold Gains, But Actionable Charts Scarce at Investor's Business Daily
11:41AM  These Two Companies Could Be Pfizer's Top Targets at Barrons.com
12-Sep-14 07:11PM  IBD 50 Names Hold Gains, But Actionable Charts Scarce at Investor's Business Daily
05:36PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
12:04PM  Activis traders eyeing breakout optionMONSTER
11-Sep-14 02:28PM  Pfizer says 'window still open' for tax inversions at Financial Times
10-Sep-14 03:45PM  Actavis' Bystolic Combination Gets Negative FDA Panel Vote Zacks
09-Sep-14 05:46PM  The Market's Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
05:10PM  FDA Advisory Committee Recommends Against Approval of Actavis' Nebivolol/Valsartan Fixed-Dose Combination NDA For Treatment Of Hypertension Benzinga
05:10PM  FDA Advisory Committee Recommends Against Approval of Actavis' Nebivolol/Valsartan Fixed-Dose Combination NDA for Treatment of Hypertension PR Newswire
04:19PM  Actavis Blood Pressure Pill Not Backed by FDA Advisers at Bloomberg
08-Sep-14 05:08PM  Today's Market Thorns, Roses, and All Time Highs... Yahoo Finance Blogs
04:20PM  Actavis' Antibiotic under FDA Review, Response in 1Q15 Zacks
05-Sep-14 08:00AM  Actavis Announces FDA Acceptance of the NDA Filing for Ceftazidime-Avibactam, a Qualified Infectious Disease Product PR Newswire
04-Sep-14 05:28PM  Today's Market Thorns, Roses, and All Time Highs Yahoo Finance Blogs
03:30PM  Actavis' Gastrointestinal Drug Under FDA Priority Review Zacks
03-Sep-14 05:41PM  The Market's Roses, Thorns, and All Time Highs... Yahoo Finance Blogs
02-Sep-14 03:10PM  Actavis Faces Shortage of Slow-Release Alzheimers Drug at Bloomberg
09:20AM  Actavis Announces FDA Acceptance for Filing of NDA for Eluxadoline PR Newswire
28-Aug-14 03:40PM  UCB Files Patent Infringement Lawsuit vs. Actavis Zacks
26-Aug-14 04:05PM  Actavis to Present at Morgan Stanley Global Healthcare Conference 2014 PR Newswire
25-Aug-14 05:40PM  Heating up: Burger King is latest in M&A frenzy at CNNMoney.com
01:44PM  Heating up: Burger King is latest in M&A frenzy at CNNMoney.com
24-Aug-14 06:43PM  Pfizer weighs options on AstraZeneca bid at Financial Times
22-Aug-14 04:05PM  Actavis Confirms Generic Neupro® Patent Challenge PR Newswire
21-Aug-14 03:30PM  Actavis Up on Positive Phase III Ceftazidime-Avibactam Data Zacks
20-Aug-14 07:00PM  AstraZeneca Is Tougher Target for Possible New Pfizer Bid Bloomberg
07:00PM  AstraZeneca Is Tougher Target for Possible New Pfizer Bid at Bloomberg
19-Aug-14 07:24AM  Actavis Announces Positive Topline Results From The Phase III Program Of Ceftazidime-Avibactam In Patients With Complicated Intra-Abdominal Infections(cIAI) PR Newswire
13-Aug-14 02:55PM  Synergy Pharma (SGYP) Posts Wider-than-Expected Loss in Q2 Zacks
12-Aug-14 01:04PM  ACTAVIS PLC Financials EDGAR Online Financials
08-Aug-14 04:30PM  ACTAVIS PLC Files SEC form 8-K, Other Events EDGAR Online
06-Aug-14 05:07PM  Stocks Muted; Keurig Green Mountain Down After Hours at Investor's Business Daily
05-Aug-14 06:30PM  4 Top Drugmakers Deliver Solid Doses Of Earnings Growth Investor's Business Daily
01:00PM  Actavis Beats on Q2 Earnings & Revs, Provides 2015 Outlook Zacks
10:29AM  Actavis Guidance Disappoints; Akorn Beats And Raises at Investor's Business Daily
09:04AM  ACTAVIS PLC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits EDGAR Online
08:44AM  Actavis reports 2Q profit AP
08:11AM  Pfizer Megadeal Still in Sight After Astra: Real M&A at Bloomberg
08:09AM  [$$] Actavis Swings to Profit at The Wall Street Journal
07:36AM  Drugmaker Actavis posts 34 pct rise in revenue Reuters
07:07AM  Q2 2014 Actavis plc Earnings Release - Before Market Open CCBN
07:01AM  ACTAVIS PLC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits EDGAR Online
07:00AM  Actavis Net Revenue Increases 34% to $2.67 Billion in Second Quarter 2014; Non-GAAP EPS Increases 70% to $3.42 PR Newswire
04-Aug-14 06:33PM  Cramer: Get this company on your radar, now! at CNBC
02:30PM  What to Watch in The Day Ahead; Tuesday, August 5 Reuters
01:03PM  3 Stocks Pulling The Drugs Industry Downward at TheStreet
02-Aug-14 08:02AM  Salix, Actavis Lead IBD 50 Drug Earnings This Week at Investor's Business Daily
01-Aug-14 08:41AM  The Zacks Analyst Blog Highlights: Medtronic, Covidien, Mylan, Actavis and Jazz Pharmaceuticals Zacks
31-Jul-14 02:51PM  Many Leading Stocks Damaged As Market Tumbles Broadly at Investor's Business Daily
10:48AM  3 Eye-Catching Health Care Stocks this Earnings Season Zacks
30-Jul-14 07:11AM  AstraZeneca buys Almirall lung drugs for up to $2.1 billion Reuters
29-Jul-14 12:46PM  Merck Pops On Good Profits, Tax Deal? at Barrons.com
28-Jul-14 06:03PM  Actavis May Give Buyers Another Chance at Investor's Business Daily
25-Jul-14 04:33PM  Activis Shares Languish Post-Forest Deal Benzinga
24-Jul-14 09:30AM  The Best Health Care Stock To Own Right Now StreetAuthority Network
09:30AM  Is This The Best Health Care Stock To Own Right Now? StreetAuthority Network
08:56AM  Is Teva Pharmaceuticals Stock Really Your Best Generic Drug Investment Option? at Motley Fool
21-Jul-14 04:30PM  Medicines360 and Actavis Announce FDA Acceptance for Filing of NDA for Levosert IUD PR Newswire
18-Jul-14 05:15PM  Synergy Pharmaceuticals Progresses with Mid-Stage Candidate Zacks
17-Jul-14 01:04PM  ACTAVIS PLC Financials EDGAR Online Financials
16-Jul-14 02:19PM  Actavis Looks To Keep Up Momentum In Spite Of Yellen's Report Benzinga
12:03PM  Mylan (MYL) Joins the Tax-Inversion Wave Zacks
11:19AM  Leon Cooperman talks up Citi, Thermo Fisher at MarketWatch
11:09AM  [video] Cooperman's best ideas for 2014 at CNBC
10:59AM  [video] Cooperman: Buy Citi, Atlas and these other stocks now at CNBC
14-Jul-14 05:30PM  Actavis Fuels Growth With Acquisitions, New Generics at Investor's Business Daily
02:54PM  Mylan in $5.3bn Abbott Laboratories deal at Financial Times
11-Jul-14 04:31PM  Actavis confirms generic Diclegis patent challenge theflyonthewall.com
04:25PM  Actavis Confirms Generic Diclegis® Patent Challenge PR Newswire
10-Jul-14 08:43AM  [video] Acorda 'firmly on the side of research': CEO at CNBC
09-Jul-14 04:10PM  Synergy Pharmaceuticals' Plecanatide to Move into Phase III Zacks
08-Jul-14 04:05PM  Actavis Confirms Generic Ampyra® Patent Challenge PR Newswire
01:28PM  Stocks Ease Off Lows; King Digital Turns Tail at Investor's Business Daily
03-Jul-14 05:03PM  ACTAVIS PLC Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition EDGAR Online
02-Jul-14 04:05PM  Impax Acquires Two Products from Actavis PR Newswire
01:04PM  ACTAVIS PLC Financials EDGAR Online Financials
08:49AM  Actavis completes acquisition of Furiex theflyonthewall.com
08:46AM  Actavis Completes Acquisition of Furiex Pharmaceuticals PR Newswire
08:00AM  Actavis Announces Final Stockholder Merger Consideration Election Results in Connection with Forest Laboratories Acquisition PR Newswire
12:01AM  Hobby Lobby Discounts Outweigh Dismay Over Court Ruling at Bloomberg
01-Jul-14 12:10PM  Actaviss Dealmaking New CEO Has Zero Plans for Sale at Bloomberg
Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. It operates in three segments: Actavis Pharma, Actavis Specialty Brands, and Anda Distribution. The Actavis Pharma segment provides generic, branded generic, and over-the-counter (OTC) pharmaceutical products. This segment sells generic prescription products primarily under the Watson Laboratories, Watson Pharma, and Actavis Pharma labels; and OTC generic products under private label. The Actavis Specialty Brands segment offers patent-protected products and trademarked off-patent products, which are marketed as branded pharmaceutical products to physicians, specifically urologists, obstetricians, dermatologists, gastroenterologists, and gynecologists. The Anda Distribution segment primarily distributes generic and selected brand pharmaceutical products, vaccines, injectables, and OTC medicines to independent pharmacies, and to alternate care providers comprising hospitals, nursing homes, and mail order pharmacies, as well as to pharmacy chains, physicians' offices, and buying groups. The company also develops and out-licenses generic pharmaceutical products primarily in Europe through its third-party business; and provides products in women's health, urology, gastroenterology, and dermatology therapeutic categories. The company has a collaboration agreement with Amgen, Inc. for the development and commercialization of various oncology antibody biosimilar medicines; and a collaboration agreement with Hanmi Pharm. Co. Ltd. to develop Hyalrheuma, a hyaluronic acid injection for arthritis pain treatment. Actavis plc was founded in 1983 and is headquartered in Parsippany, New Jersey.